Practical Guidance on Mental Health and Physician Burnout

Latest News

‘Exciting’ New Therapies, Including BTK Inhibitors and Monoclonal Antibodies, Promising for CLL

In recent years, the treatment of chronic lymphocytic leukemia (CLL) has undergone a seismic shift, with chemotherapy being replaced by a new and more effective generation of drugs. One of the "really exciting" therapies to emerge is the Bruton's tyrosine kinase inhibitors.

Learn More

‘Great Urgency’ to Understand KRAS as an Actionable Marker in Lung Cancer

As cancer treatment evolves into precision medicine, certain markers are emerging as actionable targets for therapy, including G12C inhibitors for the KRAS gene. KRAS is considered to be the most mutated oncogene in human cancers. At least three different mutations in this gene are associated with lung cancer.

Learn More

Addressing Work-Life Balance Essential for Doctors’ Mental Health

More than half of physicians surveyed say they've struggled to maintain a healthy work-life balance, and the COVID-19 pandemic has only exacerbated the problem.

Learn More

Belamaf is ‘First-In-Class’ New Therapy for Relapsed/Refractory Myeloma, But What’s Its Role in the Toolkit?

In August, the FDA granted belantamab mafodotin (Belamaf) accelerated approval for patients with relapsed or refractory multiple myeloma who've received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Learn More

Bispecific Antibodies Challenge CAR T-Cell Therapy as Multiple Myeloma Treatment Contender

The latest buzzword in multiple myeloma is bispecifics. This off-the-shelf treatment is proving to be an attractive option for patients who can't wait for CAR T-cell therapy.

Learn More

Bispecific Antibodies Offer Lymphoma Patients a Promising New Therapeutic Option

Bispecific antibodies have exciting potential as a cancer therapy, due to their ability to simultaneously bind to two targets. Right now, this treatment is only available in investigational trials, but it has shown promising outcomes for patients with relapsed-refractory lymphoma who have already undergone a transplant, CAR T-cell therapy, or other lines of treatment.

Learn More

Black Participation in Clinical Trials Is Imperative to Reduce Racial Disparities in Multiple Myeloma

By Kayle Waterhouse African Americans must be properly represented in clinical trials to ensure equal treatment for multiple myeloma and other cancers, top oncologists told SurvivorNet Connect.  Dr. Ajay Nooka, a hematologist-oncologist at the Winship Cancer Institute, says Blacks are underrepresented in clinical trials. He states that “20% of the patients that we treat for […]

Learn More

Black People are Dramatically Underrepresented in Clinical Trials

Black people have the highest death rates and shortest survival of any racial or ethnic group in the United States. Yet they are significantly underrepresented in studies evaluating the drugs that might improve their prognosis. A ProPublica analysis found that, in trials for 24 of the 31 cancer drugs approved between 2015 and 2018, less than 2% of participants were Black, even though Black Americans make up 13% of the population.

Learn More